US12098394B2 - Monooxygenase mutant and use thereof - Google Patents

Monooxygenase mutant and use thereof Download PDF

Info

Publication number
US12098394B2
US12098394B2 US17/290,749 US201817290749A US12098394B2 US 12098394 B2 US12098394 B2 US 12098394B2 US 201817290749 A US201817290749 A US 201817290749A US 12098394 B2 US12098394 B2 US 12098394B2
Authority
US
United States
Prior art keywords
seq
polypeptide
replaced
amino acid
position corresponding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/290,749
Other versions
US20220002683A1 (en
Inventor
Hao Hong
Gage JAMES
Jiangping Lu
Xuecheng JIAO
Na Zhang
Kejian Zhang
Rui Li
Yu Zhang
Yiming Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asymchem Laboratories Tianjin Co Ltd
Original Assignee
Asymchem Laboratories Tianjin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asymchem Laboratories Tianjin Co Ltd filed Critical Asymchem Laboratories Tianjin Co Ltd
Assigned to ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. reassignment ASYMCHEM LABORATORIES (TIANJIN) CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HONG, Hao, James, Gage, JIAO, Xuecheng, LI, RUI, LU, JIANGPING, YANG, YIMING, ZHANG, KEJIAN, ZHANG, NA, ZHANG, YU
Publication of US20220002683A1 publication Critical patent/US20220002683A1/en
Application granted granted Critical
Publication of US12098394B2 publication Critical patent/US12098394B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P11/00—Preparation of sulfur-containing organic compounds

Definitions

  • the disclosure relates to the field of biotechnologies, and in particular to a monooxygenase mutant and use thereof.
  • Chiral sulfoxides widely exist in natural world, and are structural units of many important bioactive molecules, as well as important intermediates for synthesis of natural products and chiral drugs. Many chiral sulfoxides contain one or more chiral centers. Pharmacological activities, metabolic processes, metabolic rates, and toxicities of the different chiral drugs are significantly different. Generally, one enantiomer is effective, while another enantiomer is low-effective or non-effective, even toxic. Therefore, how to construct compounds containing the chiral centers efficiently and stereoselectively has great significance in medical research and development.
  • Baeyer Villiger monooxygenases belong to flavin monooxygenases, it is usually used to stereoselectively oxidize chain and cyclic ketones to generate corresponding esters or lactones, and may also catalyze electrophilic oxidation reactions of sulfur, nitrogen and phosphorus. At the same time, the BVMOs may also catalyze the nucleophilic oxidation reactions of ketone and boron.
  • the BVMOs have important applications in the synthesis of the chiral drugs. For example, it may catalyze oxidation of a sulfur-containing chiral precursor, and is used in synthesis of chiral drugs Modafinil and Omeprazole (CN105695425A).
  • the BVMOs Although several of the BVMOs are commercially applied, the BVMOs generally have problems such as low enzyme activity, low enzyme stability, and generation of a by-product sulfone. Generally speaking, a wild-type enzyme may be transformed by us through means of directed evolution to improve various properties of the enzyme, and thereby it may be used in production ( Chem. Rev. 2011, 111: 4165-4222).
  • the disclosure aims to provide a monooxygenase mutant and use thereof, as to solve technical problems in the prior art that a monooxygenase is low in enzyme activity and a by-product sulfone is higher in content.
  • a monooxygenase mutant is provided.
  • An amino acid sequence of the monooxygenase mutant is obtained by mutation of an amino acid sequence shown in SEQ ID NO: 1, and the mutation at least includes one of the following mutation sites: 45-th site, 95-th site, 106-th site, 108-th site, 114-th site, 186-th site, 190-th site, 191-th site, 249-th site, 257-th site, 393-th site, 436-th site, 499-th site, 500-th site, 501-th site, 503-th site, 504-th site, 559-th site, and 560-th site, and the mutation is that a methionine in the 45-th site is mutated into a threonine; an alanine in the 95-th site is mutated into a threonine; a cysteine in the 106-th site is mutated into a
  • the mutation at least includes one of the following mutation site combinations: a tyrosine in the 559-th site is mutated into a lysine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a proline and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a glutamine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyros
  • the mutation at least includes one of the following mutation site combinations: a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a methionine in the 45-th site mutated into a threonine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a cysteine in the 257-th site is mutated into an alanine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a cysteine in the 249-th site is mutated into a valine; a proline in the 190-th site is mutated into a leucine, a tyros
  • a recombinant plasmid contains the above DNA molecule.
  • the recombinant plasmid is pET-22b(+), pET-22b(+), pET-3a(+), pET-3d(+), pET-11a(+), pET-12a(+), pET-14b(+), pET-15b(+), pET-16b(+), pET-17b(+), pET-19b(+), pET-20b(+), pET-21a(+), pET-23a(+), pET-23b(+), pET-24a(+), pET-25b(+), pET-26b(+), pET-27b(+), pET-28a(+), pET-29a(+), pET-30a(+), pET-31b(+), pET-32a(+), pET-35b(+), pET-38b(+), pET-39b(+), pET-40b(+), PET-41a(+),
  • a host cell contains the above recombinant plasmid.
  • the host cell includes a prokaryotic cell, a yeast or a eukaryotic cell; and preferably, the prokaryotic cell is an E. coli BL21 cell or an E. coli DH5 ⁇ competent cell.
  • a method for producing a chiral sulfoxide includes a step of performing a catalytic monooxygenation reaction on a thioether compound by a monooxygenase, and the monooxygenase is the above monooxygenase mutant.
  • the monooxygenase is cell lysate enzyme solution, a whole cell, freeze-dried enzyme powder, a freeze-dried cell, an immobilized enzyme or an immobilized cell of the monooxygenase mutant.
  • a reaction system of the monooxygenation reaction further includes a cofactor
  • the cofactor is NAD/NADH and/or NADP/NADPH
  • a cofactor circulation system includes glucose and glucose dehydrogenase, formate and formate dehydrogenase, glucose 6-phosphate and glucose-6-phosphate dehydrogenase, or secondary alcohol and secondary alcohol dehydrogenase.
  • an addition amount of the monooxygenase in the reaction system of the monooxygenation reaction is 0.1 to 10 times of a substrate mass.
  • a temperature of the monooxygenation reaction is 10 ⁇ 50° C., preferably 30° C.
  • the monooxygenation reaction is performed at a pH of 7 ⁇ 10, preferably a pH of 9.
  • the monooxygenase mutant of the disclosure is based on the monooxygenase shown in the SEQ ID NO: 1, and mutated through a method of site-directed mutagenesis, thereby the amino acid sequence thereof is changed to achieve changes in protein structure and function, and the monooxygenase with the above mutation sites is obtained by a method of directional screening.
  • the monooxygenase mutant of the disclosure has an advantage of greatly improving the enzyme activity, thereby a cost in industrial production of the chiral sulfoxide is greatly reduced.
  • a monooxygenase derived from Brachymonas petroleovorans may catalyze conversion of (3-chlorobenzyl) dimethyl sulfide high-selectively.
  • an ee value of a catalytic product of the monooxygenase derived from the Brachymonas petroleovorans is only 43.9%.
  • the monooxygenase BVMO derived from Rhodococcus ruber -SD1 may catalyze the conversion of the substrate (1-(3-chlorophenyl)cyclopropyl) methyl sulfide with higher selectivity.
  • the ee value is 99%, but the activity thereof is lower, a by-product sulfone (peroxide) after a reaction is larger in content, an amount of an added enzyme during the reaction is larger, and separation and extraction of a product are difficult.
  • the inventor of the disclosure aims to improve the activity of the BVMO, reduce the amount of the used enzyme, improve the selectivity of the enzyme, and reduce the content of the by-product sulfone through a method of directed evolution.
  • the inventor of the disclosure improves the activity and selectivity of the monooxygenase SEQ ID NO: 1 (MTTSIDREALRRKYAEERDKRIRPDGNDQYIRLDHVDGWSHDPYMPITPREPKLDHVTFA FIGGGFSGLVTAARLRESGVESVRIIDKAGDFGGVWYWNRYPGAMCDTAAMVYMPLLEET GYMPTEKYAHGPEILEHCQRIGKHYDLYDDALFHTEVTDLVWQEHDQRWRISTNRGDHFT AQFVGMGTGPLHVAQLPGIPGIESFRGKSFHTSRWDYDYTGGDALGAPMDKLADKRVAVI GTGATAVQCVPELAKYCRELYVVQRTPSAVDERGNHPIDEKWFAQIATPGWQKRWLDSFT AIWDGVLTDPSELAIEHEDLVQDGWTALGQRMRAAVGSVPIEQYSPENVQRALEEADDEQ MERIRARVDEIVTDPATAAQLKAWFRQMCKRPCFHDDYLPAF
  • a mutation site is introduced into the monooxygenase SEQ ID NO: 1 in a mode of a whole plasmid PCR, and the activity of mutants and the content of the by-product sulfone are detected, the mutants with the improved activity or reduced by-product sulfone content are selected.
  • the BVMO is used as a template, 34 pairs of site-directed mutagenesis primers are designed (M45T, V95I, C106S, D107A, T108I, T108S, M114L, M186I, P190F, P190L, L191V, L191A, C249V, C257A, C393V, C436S, L499A, L499G, G500L, S501T, N502Q, I503G, I503A, I503M, P504F, G558V, G558N, Y559F, Y559L, Y559A, Y560F, Y560L, Y560A, C555S).
  • a method of the site-directed mutagenesis is used, and pET-28b(+) is used as an expression vector, to obtain a mutant plasmid with a target gene.
  • site-directed mutagenesis refers to introduction of desired changes (usually changes represented in favorable directions) in a target DNA fragment (may be a genome, and may also be a plasmid) through methods such as a polymerase chain reaction (PCR), including addition, deletion, point mutation and the like of a base.
  • PCR polymerase chain reaction
  • the site-directed mutagenesis may quickly and efficiently improve characters and representation of a target protein expressed by a DNA, and it is a very useful method in gene research work.
  • the method of introducing the site-directed mutagenesis using the whole plasmid PCR is simple and effective, and is a more commonly used method at present.
  • a principle thereof is that a pair of primers (forward and reverse) containing mutation sites are annealed with the template plasmid, and then “circularly extended” by a polymerase.
  • the so-called circular extension means that the polymerase extends the primers according to the template, returns to a 5′-end of the primers for termination after one circle, and then undergoes repeated heating and annealing extension cycles. This reaction is different from rolling circle amplification and may not form multiple tandem copies.
  • Extension products of the forward and reverse primers are annealed and paired to form an open-circle plasmid with a nick.
  • An extension product of Dpn I digestion because the original template plasmid is derived from conventional E. coli , is modified by dam methylation, and is chopped because it is sensitive to Dpn I, but a plasmid with a mutation sequence synthesized in vitro is not digested because there is no methylation, so it is successfully transformed in the subsequent transformation, and a clone of the mutant plasmid may be obtained.
  • the mutant plasmid obtained above is transformed into E. coli cells, and overexpressed in E. coli . Then, a crude enzyme is obtained by ultrasonically breaking the cells. The best conditions for inducing expression of an amino acid dehydrogenase: 25° C., inducing with 0.1 mM IPTG overnight.
  • a monooxygenase mutant is provided.
  • An amino acid sequence of the monooxygenase mutant is obtained by mutation of an amino acid sequence shown in SEQ ID NO: 1, and the mutation at least includes one of the following mutation sites: 45-th site, 95-th site, 106-th site, 108-th site, 114-th site, 186-th site, 190-th site, 191-th site, 249-th site, 257-th site, 393-th site, 436-th site, 499-th site, 500-th site, 501-th site, 503-th site, 504-th site, 559-th site, and 560-th site, and the mutation is that a methionine in the 45-th site is mutated into a threonine; an alanine in the 95-th site is mutated into a threonine; a cysteine in the 106-th site is mutated into a serine; a
  • the mutation at least includes one of the following mutation site combinations: a tyrosine in the 559-th site is mutated into a lysine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a proline and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a glutamine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyros
  • the mutation at least includes one of the following mutation site combinations: a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a methionine in the 45-th site mutated into a threonine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a cysteine in the 257-th site is mutated into an alanine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a cysteine in the 249-th site is mutated into a valine; a proline in the 190-th site is mutated into a leucine, a tyros
  • the monooxygenase mutant of the disclosure is based on the monooxygenase shown in the SEQ ID NO: 1, and mutated through a method of site-directed mutagenesis, thereby the amino acid sequence thereof is changed to achieve changes in protein structure and function, and the monooxygenase with the above mutation sites is obtained by a method of directional screening.
  • the monooxygenase mutant of the disclosure has an advantage of greatly improving the enzyme activity, and the selectivity of the enzyme is greatly improved, and the by-product sulfone content is greatly reduced, thereby a cost in industrial production of the chiral sulfoxide is greatly reduced.
  • a DNA molecule encodes the above monooxygenase mutant.
  • the monooxygenase obtained by the above DNA encoding improves the enzyme activity and the enzyme selectivity, reduces the content of the by-product sulfone, reduces the amount of the added enzyme in industrial production of a chiral sulfoxide, and reduces the difficulty of post-treatment separation and purification.
  • the above DNA molecule of the disclosure may also exist in the form of an “expression cassette”.
  • the “expression cassette” refers to a linear or circular nucleic acid molecule, including DNA and RNA sequences that may direct the expression of a specific nucleotide sequence in an appropriate host cell. Generally speaking, it includes a promoter operatively linked with a target nucleotide, and optionally it is operatively linked with a termination signal and/or other regulatory elements.
  • the expression cassette may also include sequences required for proper translation of the nucleotide sequence.
  • An encoding region usually encodes the target protein, but also encodes a target functional RNA in a sense or antisense direction, such as an antisense RNA or an untranslated RNA.
  • the expression cassette containing a target polynucleotide sequence may be chimeric, it means that at least one of components thereof is heterologous to at least one of the other components thereof.
  • the expression cassette may also naturally exist, but is obtained by efficient recombination for heterologous expression.
  • a recombinant plasmid is provided.
  • the recombinant plasmid contains any one of the above DNA molecules.
  • the DNA molecule in the above recombinant plasmid is placed in a suitable position of the recombinant plasmid, so that the above DNA molecule may be replicated, transcripted or expressed correctly and smoothly.
  • a qualifier used in the disclosure to define the above DNA molecule is “containing”, it does not mean that other sequences which are not related to a function thereof may be arbitrarily added to both ends of the DNA sequence. It is known by those skilled in the art that in order to meet requirements of a recombination operation, it is necessary to add appropriate restriction endonuclease digestion sites at both ends of the DNA sequence, or add additional a start codon, a stop codon and the like. Therefore, if a closed expression is used to limit, these situations may not be truly covered.
  • Plasmid used in the disclosure includes any plasmids, cosmids, bacteriophages or agrobacterium binary nucleic acid molecules in double-stranded or single-stranded linear or circular form, preferably a recombinant expression plasmid, it may be a prokaryotic expression plasmid, and may also be a eukaryotic expression plasmid, but preferably the prokaryotic expression plasmid.
  • the recombinant plasmid is selected from pET-22b(+), pET-22b(+), pET-3a(+), pET-3d(+)), pET-11a(+), pET-12a(+), pET-14b(+), pET-15b(+), pET-16b(+), pET-17b(+), pET-19b(+), PET-20b(+), pET-21a(+), pET-23a(+), pET-23b(+), pET-24a(+), pET-25b(+), pET-26b(+), pET-27b(+), pET-28a(+), pET-29a(+), pET-30a(+), pET-31b(+), pET-32a(+), pET-35b(+), pET-38b(+), pET-39b(+), pET-40b(+), pET
  • a host cell contains any one of the above recombinant plasmids.
  • the host cell suitable for the disclosure includes but is not limited to a prokaryotic cell, a yeast or a eukaryotic cell.
  • the prokaryotic cell is eubacteria, for example, gram-negative bacteria or gram-positive bacteria. More preferably, the prokaryotic cell is an E. coli BL21 cell or an E. coli DH5 ⁇ competent cell.
  • the best conditions for inducing the expression of the monooxygenase 25° C., inducing with 0.1 mM IPTG for 16 h.
  • the mutant plasmid is transformed into the E. coli cells, and then a crude enzyme is obtained by a method of ultrasonically breaking the cells.
  • a method for producing a chiral sulfoxide includes a step of performing a catalytic monooxygenation reaction on a thioether compound by a monooxygenase, herein the monooxygenase is any one of the above monooxygenase mutants. Because the above monooxygenase mutant of the disclosure has higher enzyme catalytic activity and higher selectivity, the chiral sulfoxide prepared by using the monooxygenase mutant of the disclosure may not only reduce the production cost, but also an ee value of the obtained chiral sulfoxide is greater than 99%, and a de value is greater than 99%.
  • the thioether compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
  • R 1 and R 2 are each independently a C 1 ⁇ C 8 alkyl, a C 5 ⁇ C 10 cycloalkyl, a C 5 ⁇ C 10 aryl or a C 5 ⁇ C 10 heteroaryl, or the R 1 and R 2 together with a carbon on a carbonyl group form a C 5 ⁇ C 10 heterocyclic group, a C 5 ⁇ C 10 carbocyclic group or a C 5 ⁇ C 10 heteroaryl, heteroatoms in the C 5 ⁇ C 10 heterocyclic group and C 5 ⁇ C 10 heteroaryl are each independently selected from at least one of nitrogen, oxygen and sulfur, and an aryl in the C 5 ⁇ C 10 aryl, a heteroaryl in the C 5 ⁇ C 10 heteroaryl, a carbocyclic group in the C 5 ⁇ C 10 carbocyclic group or a heterocyclic group in the C 5 ⁇ C 10 heterocyclic group is each independently unsubstituted or substituted with at least one group of a hal
  • the monooxygenase may be cell lysate enzyme solution, a whole cell, freeze-dried enzyme powder, a freeze-dried cell, an immobilized enzyme or an immobilized cell of the monooxygenase mutant.
  • the mutant obtained by screening is cultured in a shake flask, and then subjected to an amplification reaction.
  • a transformation effect of a single-site mutant is higher than that of a female parent, but it does not achieve the desired effect.
  • a combined saturation mutation may obtain a mutant with a synergistic effect between several mutation sites, and compositions of an amino acid thereof may be optimized and combined. Results are shown in Table 2.
  • Combination of mutation sites may obtain the better mutant. Therefore, the mutation sites are randomly recombined by a method of DNA shuffling, to build a mutation library, and then it is screened to try to get the better mutant.
  • DNA shuffling is sexual recombination of genes at a molecular level.
  • a group of homologous genes are digested with a nuclease I into random fragments, a library is formed by these random fragments, and PCR amplification is performed by using these random fragments as primers and templates mutually. While one gene copy fragment is used as a primer for another gene copy, template exchange and gene recombination occur.
  • the mutant obtained by screening is cultured in a shake flask, and then subjected to an amplification reaction.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

An amino acid sequence of the monooxygenase mutant is obtained by mutation of an amino acid sequence shown in SEQ ID NO: 1, and the mutation at least includes one of the following mutation sites: 45-th site, 95-th site, 106-th site, 108-th site, 114-th site, 186-th site, 190-th site, 191-th site, 249-th site, 257-th site, 393-th site, 436-th site, 499-th site, 500-th site, 501-th site, 503-th site, 504-th site, 559-th site, and 560-th site.

Description

INCORPORATION OF SEQUENCE LISTING
This application contains a sequence listing submitted in Computer Readable Form (CRF). The CFR file containing the sequence listing entitled “PAL2344706_ST25”, which was created on Apr. 28, 2021, and is 7,955 bytes in size. The information in the sequence listing is incorporated herein by reference in its entirety.
TECHNICAL FIELD
The disclosure relates to the field of biotechnologies, and in particular to a monooxygenase mutant and use thereof.
BACKGROUND
Chiral sulfoxides widely exist in natural world, and are structural units of many important bioactive molecules, as well as important intermediates for synthesis of natural products and chiral drugs. Many chiral sulfoxides contain one or more chiral centers. Pharmacological activities, metabolic processes, metabolic rates, and toxicities of the different chiral drugs are significantly different. Generally, one enantiomer is effective, while another enantiomer is low-effective or non-effective, even toxic. Therefore, how to construct compounds containing the chiral centers efficiently and stereoselectively has great significance in medical research and development.
Baeyer Villiger monooxygenases (BVMOs) belong to flavin monooxygenases, it is usually used to stereoselectively oxidize chain and cyclic ketones to generate corresponding esters or lactones, and may also catalyze electrophilic oxidation reactions of sulfur, nitrogen and phosphorus. At the same time, the BVMOs may also catalyze the nucleophilic oxidation reactions of ketone and boron. The BVMOs have important applications in the synthesis of the chiral drugs. For example, it may catalyze oxidation of a sulfur-containing chiral precursor, and is used in synthesis of chiral drugs Modafinil and Omeprazole (CN105695425A).
Although several of the BVMOs are commercially applied, the BVMOs generally have problems such as low enzyme activity, low enzyme stability, and generation of a by-product sulfone. Generally speaking, a wild-type enzyme may be transformed by us through means of directed evolution to improve various properties of the enzyme, and thereby it may be used in production (Chem. Rev. 2011, 111: 4165-4222).
SUMMARY
The disclosure aims to provide a monooxygenase mutant and use thereof, as to solve technical problems in the prior art that a monooxygenase is low in enzyme activity and a by-product sulfone is higher in content.
In order to achieve the above purpose, according to one aspect of the disclosure, a monooxygenase mutant is provided. An amino acid sequence of the monooxygenase mutant is obtained by mutation of an amino acid sequence shown in SEQ ID NO: 1, and the mutation at least includes one of the following mutation sites: 45-th site, 95-th site, 106-th site, 108-th site, 114-th site, 186-th site, 190-th site, 191-th site, 249-th site, 257-th site, 393-th site, 436-th site, 499-th site, 500-th site, 501-th site, 503-th site, 504-th site, 559-th site, and 560-th site, and the mutation is that a methionine in the 45-th site is mutated into a threonine; an alanine in the 95-th site is mutated into a threonine; a cysteine in the 106-th site is mutated into a serine; a threonine in the 108-th site is mutated into a serine; a methionine in the 114-th site is mutated into a leucine, a methionine in the 186-th site is mutated into an isoleucine, a proline in the 190-th site is mutated into a glutamine, a glycine, an arginine, an asparagine, a glutamic acid, a valine, a threonine, an isoleucine, a histidine, a tyrosine, a phenylalanine or a leucine, a leucine in the 191-th site is mutated into a valine, a cysteine in the 249-th site is mutated into a valine, a cysteine in the 257-th site is mutated into an alanine, a cysteine in the 393-th site is mutated into a valine, a cysteine in the 436-th site is mutated into a serine, a leucine in the 499-th site is mutated into an alanine, a glycine in the 500-th site is mutated into a leucine, a serine in the 501-th site is mutated into a threonine, an isoleucine in the 503-th site is mutated into an alanine, a proline in the 504-th site is mutated into a threonine, a valine or a serine, a tyrosine in the 559-th site is mutated into a phenylalanine, a lysine, a methionine, a proline, a glutamine, an asparagine, a serine, an arginine, a valine, an aspartic acid, an isoleucine, a serine, a leucine or an alanine and a tyrosine in the 560-th site is mutated into a phenylalanine, a leucine, a serine, a proline, a methionine, or a alanine; or the amino acid sequence of the monooxygenase mutant is an amino acid sequence having the mutation sites in the mutated amino acid sequence, and having more than 80% of homology with the mutated amino acid sequence.
Further, the mutation at least includes one of the following mutation site combinations: a tyrosine in the 559-th site is mutated into a lysine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a proline and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a glutamine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an asparagines and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a threonine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an arginine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a valine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an aspartic acid and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an isoleucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an alanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a serine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 560-th site is mutated into a serine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a glutamine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th is mutated into a glycine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into an arginine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into an asparagine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a phenylalanine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a glutamic acid; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a valine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a threonine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into an isoleucine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a histidine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a tyrosine; a tyrosine in the 560-th site is mutated into a proline and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an alanine, a tyrosine in the 560-th site is mutated into a methionine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an alanine, a tyrosine in the 560-th site is mutated into an phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an alanine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a phenylalanine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a phenylalanine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th is mutated into a leucine; a tyrosine in the 559-th site is mutated into a histidine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a lysine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a leucine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a leucine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a glutamine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an asparagine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a proline, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a glutamine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a serine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a serine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a serine, a tyrosine in the 560-th site is mutated into a proline and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a threonine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a threonine, a tyrosine in the 560-th site is mutated into a glycine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a threonine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a valine, a tyrosine in the 560-th site is mutated into an alanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a valine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a valine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a valine, a tyrosine in the 560-th site is mutated into a glutamine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a proline in the 504-th site is mutated into an alanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a proline in the 504-th site is mutated into an isoleucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, an asparagines in the 503-th site is mutated into a valine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a proline in the 504-th site is mutated into a threonine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a proline in the 504-th site is mutated into a valine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a proline in the 504-th site is mutated into a serine and a proline in the 190-th site is mutated into a leucine; and
preferably, the mutation at least includes one of the following mutation site combinations: a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a methionine in the 45-th site mutated into a threonine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a cysteine in the 257-th site is mutated into an alanine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a cysteine in the 249-th site is mutated into a valine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a cysteine in the 393-th site is mutated into a valine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a methionine in the 186-th site is mutated into an isoleucine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine, a cysteine in the 249-th site is mutated into a valine and a cysteine in the 393-th site is mutated into a valine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine, a cysteine in the 249-th site is mutated into a valine, a cysteine in the 393-th site is mutated into a valine and a cysteine in the 257-th site is mutated into an alanine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine, a cysteine in the 249-th site is mutated into a valine, a cysteine in the 393-th site is mutated into a valine, a cysteine in the 257-th site is mutated into an alanine and a methionine in the 45-th site is mutated into a threonine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine, a cysteine in the 249-th site is mutated into a valine, a cysteine in the 393-th site is mutated into a valine, a cysteine in the 257-th site is mutated into an alanine, a methionine in the 45-th site is mutated into a threonine and a methionine in the 186-th site is mutated into an isoleucine. According to another aspect of the disclosure, a DNA molecule is provided. The DNA molecule encodes the above monooxygenase mutant.
According to another aspect of the disclosure, a recombinant plasmid is provided. The recombinant plasmid contains the above DNA molecule.
Further, the recombinant plasmid is pET-22b(+), pET-22b(+), pET-3a(+), pET-3d(+), pET-11a(+), pET-12a(+), pET-14b(+), pET-15b(+), pET-16b(+), pET-17b(+), pET-19b(+), pET-20b(+), pET-21a(+), pET-23a(+), pET-23b(+), pET-24a(+), pET-25b(+), pET-26b(+), pET-27b(+), pET-28a(+), pET-29a(+), pET-30a(+), pET-31b(+), pET-32a(+), pET-35b(+), pET-38b(+), pET-39b(+), pET-40b(+), PET-41a(+), pET-41b(+), pET-42a(+), pET-43a(+), pET-43b(+), pET-44a(+), pET-49b(+), pQE2, pQE9, pQE30, pQE31, pQE32, pQE40, pQE70, pQE80, pRSET-A, pRSET-B, pRSET-C, pGEX-5X-1, pGEX-6p-1, pGEX-6p-2, pBV220, pBV221, pBV222, pTrc99A, pTwin1, pEZZ18, pKK232-18, pUC-18 or pUC-19.
According to another aspect of the disclosure, a host cell is provided. The host cell contains the above recombinant plasmid.
Further, the host cell includes a prokaryotic cell, a yeast or a eukaryotic cell; and preferably, the prokaryotic cell is an E. coli BL21 cell or an E. coli DH5α competent cell.
According to another aspect of the disclosure, a method for producing a chiral sulfoxide is provided. The method includes a step of performing a catalytic monooxygenation reaction on a thioether compound by a monooxygenase, and the monooxygenase is the above monooxygenase mutant.
Further, the thioether compound is
Figure US12098394-20240924-C00001
herein R1 and R2 are each independently a C1˜C8 alkyl, a C5˜C10 cycloalkyl, a C5˜C10 aryl or a C5˜C10 heteroaryl, or the R1 and R2 together with a carbon on a carbonyl group form a C5˜C10 heterocyclic group, a C5˜C10 carbocyclic group or a C5˜C10 heteroaryl, heteroatoms in the C5˜C10 heterocyclic group and C5˜C10 heteroaryl are each independently selected from at least one of nitrogen, oxygen and sulfur, and an aryl in the C5˜C10 aryl, a heteroaryl in the C5˜C10 heteroaryl, a carbocyclic group in the C5˜C10 carbocyclic group or a heterocyclic group in the C5˜C10 heterocyclic group is each independently unsubstituted or substituted with at least one group of a halogen, an alkoxy or an alkyl.
Further, the thioether compound is
Figure US12098394-20240924-C00002
Further, the monooxygenase is cell lysate enzyme solution, a whole cell, freeze-dried enzyme powder, a freeze-dried cell, an immobilized enzyme or an immobilized cell of the monooxygenase mutant.
Further, a reaction system of the monooxygenation reaction further includes a cofactor, the cofactor is NAD/NADH and/or NADP/NADPH, and a cofactor circulation system includes glucose and glucose dehydrogenase, formate and formate dehydrogenase, glucose 6-phosphate and glucose-6-phosphate dehydrogenase, or secondary alcohol and secondary alcohol dehydrogenase.
Further, an addition amount of the monooxygenase in the reaction system of the monooxygenation reaction is 0.1 to 10 times of a substrate mass.
Further, a temperature of the monooxygenation reaction is 10˜50° C., preferably 30° C.
Further, the monooxygenation reaction is performed at a pH of 7˜10, preferably a pH of 9. The monooxygenase mutant of the disclosure is based on the monooxygenase shown in the SEQ ID NO: 1, and mutated through a method of site-directed mutagenesis, thereby the amino acid sequence thereof is changed to achieve changes in protein structure and function, and the monooxygenase with the above mutation sites is obtained by a method of directional screening. The monooxygenase mutant of the disclosure has an advantage of greatly improving the enzyme activity, thereby a cost in industrial production of the chiral sulfoxide is greatly reduced.
DETAILED DESCRIPTION OF THE EMBODIMENTS
It is to be noted that embodiments in the present application and features in the embodiments may be combined with each other in the case without conflicting. The disclosure is described in detail below in combination with the embodiments.
A monooxygenase derived from Brachymonas petroleovorans may catalyze conversion of (3-chlorobenzyl) dimethyl sulfide high-selectively. However, for conversion of (1-(3-chlorophenyl)cyclopropyl)methyl sulfide, an ee value of a catalytic product of the monooxygenase derived from the Brachymonas petroleovorans is only 43.9%. After screening other monooxygenases, it is discovered that the monooxygenase BVMO derived from Rhodococcus ruber-SD1 may catalyze the conversion of the substrate (1-(3-chlorophenyl)cyclopropyl) methyl sulfide with higher selectivity. The ee value is 99%, but the activity thereof is lower, a by-product sulfone (peroxide) after a reaction is larger in content, an amount of an added enzyme during the reaction is larger, and separation and extraction of a product are difficult. The inventor of the disclosure aims to improve the activity of the BVMO, reduce the amount of the used enzyme, improve the selectivity of the enzyme, and reduce the content of the by-product sulfone through a method of directed evolution.
The inventor of the disclosure improves the activity and selectivity of the monooxygenase SEQ ID NO: 1 (MTTSIDREALRRKYAEERDKRIRPDGNDQYIRLDHVDGWSHDPYMPITPREPKLDHVTFA FIGGGFSGLVTAARLRESGVESVRIIDKAGDFGGVWYWNRYPGAMCDTAAMVYMPLLEET GYMPTEKYAHGPEILEHCQRIGKHYDLYDDALFHTEVTDLVWQEHDQRWRISTNRGDHFT AQFVGMGTGPLHVAQLPGIPGIESFRGKSFHTSRWDYDYTGGDALGAPMDKLADKRVAVI GTGATAVQCVPELAKYCRELYVVQRTPSAVDERGNHPIDEKWFAQIATPGWQKRWLDSFT AIWDGVLTDPSELAIEHEDLVQDGWTALGQRMRAAVGSVPIEQYSPENVQRALEEADDEQ MERIRARVDEIVTDPATAAQLKAWFRQMCKRPCFHDDYLPAFNRPNTHLVDTGGKGVERIT ENGVVVAGVEYEVDCIVYASGFEFLGTGYTDRAGFDPTGRDGVKLSEHWAQGTRTLHGM HTYGFPNLFVLQLMQGAALGSNIPNFVEAARVVAAIVDHVLSTGTSSVETTKEAEQAWV QLLLDHGRPLGNPECTPGYYNNEGKPAELKDRLNVGYPAGSAAFFRMMDHWLAAGSFD GLTFR) and a corresponding base sequence SEQ ID NO: 2 (atgacaaccagtatcgatcgcgaggccctgcgccgcaaatatgccgaagagcgcgataaacgcatccgcccggatggca acgatcagtatattcgcctggatcatgttgacggttggagccatgacccttatatgccgatcaccccgcgcgagccgaaactgg accatgttacatttgcattcatcggcggcggttttagcggtctggtgaccgccgcacgtctgcgtgaaagtggcgtggagagtgtt cgcatcatcgacaaagcaggcgatttcggcggcgtttggtattggaaccgttatccgggtgccatgtgcgataccgcagcaatg gtgtacatgcctctgctggaagagaccggctacatgccgacagaaaaatatgctcatggtccggagattctggagcactgtca gcgcatcggcaaacactacgacctgtatgacgatgccctgttccataccgaagttaccgacctggtgtggcaggagcatgatc agcgttggcgcatcagcacaaaccgcggtgaccatttcaccgcacagttcgttggcatgggtaccggcccgctgcacgttgca cagctgccgggtattccgggtatcgagagcttccgtggtaagagcttccataccagccgctgggactatgactatacaggtggc gacgcactgggcgcacctatggacaaactggcagacaaacgcgtggcagtgattggtaccggcgcaaccgccgttcagtgc gttccggaactggccaagtactgccgcgaactgtatgtggttcagcgcaccccgagtgccgttgatgaacgcggcaaccatcc gatcgatgaaaagtggttcgcccagattgccacacctggttggcagaaacgctggctggatagctttaccgcaatctgggatgg tgtgctgacagatccgagcgaactggccatcgagcatgaagacctggtgcaggatggttggacagcactgggtcagcgcatg cgtgcagccgtgggtagcgttccgattgaacagtatagcccggagaacgtgcagcgtgccctggaagaggccgacgatgaa cagatggaacgcattcgcgcacgtgtggatgagattgtgaccgatcctgccaccgccgcccagctgaaagcatggtttcgcca gatgtgcaagcgtccgtgcttccacgatgactatctgcctgcattcaaccgcccgaatacccatctggtggacacaggtggcaa aggcgtggagcgcattaccgaaaacggtgtggtggttgcaggtgtggaatatgaggtggactgcatcgtgtacgccagtggctt cgagttcttaggcaccggttatacagaccgtgcaggtttcgatccgaccggccgtgatggcgttaaactgagcgaacattgggc ccaaggcacacgtaccctgcatggcatgcatacctacggctttccgaacctgtttgtgctgcagctgatgcagggtgcagccctg ggtagcaacatcccgcacaactttgttgaagccgcccgcgtggtggccgcaattgttgatcatgtgctgagcacaggcaccagt agcgttgaaaccaccaaggaagccgaacaagcctgggtgcagctgctgctggatcacggtcgccctctgggcaacccgga gtgtacacctggttattacaataatgaaggcaaaccggccgaactgaaggaccgtctgaacgttggctatccggccggtagcg ccgccttttttcgtatgatggaccactggctggcagccggcagttttgatggcctgacattccgctaa), reduces the amount of the used enzyme, and reduces the content of the by-product sulfone through the method of directed evolution. Firstly, a mutation site is introduced into the monooxygenase SEQ ID NO: 1 in a mode of a whole plasmid PCR, and the activity of mutants and the content of the by-product sulfone are detected, the mutants with the improved activity or reduced by-product sulfone content are selected.
The BVMO is used as a template, 34 pairs of site-directed mutagenesis primers are designed (M45T, V95I, C106S, D107A, T108I, T108S, M114L, M186I, P190F, P190L, L191V, L191A, C249V, C257A, C393V, C436S, L499A, L499G, G500L, S501T, N502Q, I503G, I503A, I503M, P504F, G558V, G558N, Y559F, Y559L, Y559A, Y560F, Y560L, Y560A, C555S). A method of the site-directed mutagenesis is used, and pET-28b(+) is used as an expression vector, to obtain a mutant plasmid with a target gene.
Herein, site-directed mutagenesis: refers to introduction of desired changes (usually changes represented in favorable directions) in a target DNA fragment (may be a genome, and may also be a plasmid) through methods such as a polymerase chain reaction (PCR), including addition, deletion, point mutation and the like of a base. The site-directed mutagenesis may quickly and efficiently improve characters and representation of a target protein expressed by a DNA, and it is a very useful method in gene research work.
The method of introducing the site-directed mutagenesis using the whole plasmid PCR is simple and effective, and is a more commonly used method at present. A principle thereof is that a pair of primers (forward and reverse) containing mutation sites are annealed with the template plasmid, and then “circularly extended” by a polymerase. The so-called circular extension means that the polymerase extends the primers according to the template, returns to a 5′-end of the primers for termination after one circle, and then undergoes repeated heating and annealing extension cycles. This reaction is different from rolling circle amplification and may not form multiple tandem copies. Extension products of the forward and reverse primers are annealed and paired to form an open-circle plasmid with a nick. An extension product of Dpn I digestion, because the original template plasmid is derived from conventional E. coli, is modified by dam methylation, and is chopped because it is sensitive to Dpn I, but a plasmid with a mutation sequence synthesized in vitro is not digested because there is no methylation, so it is successfully transformed in the subsequent transformation, and a clone of the mutant plasmid may be obtained.
The mutant plasmid obtained above is transformed into E. coli cells, and overexpressed in E. coli. Then, a crude enzyme is obtained by ultrasonically breaking the cells. The best conditions for inducing expression of an amino acid dehydrogenase: 25° C., inducing with 0.1 mM IPTG overnight.
According to a typical implementation mode of the disclosure, a monooxygenase mutant is provided. An amino acid sequence of the monooxygenase mutant is obtained by mutation of an amino acid sequence shown in SEQ ID NO: 1, and the mutation at least includes one of the following mutation sites: 45-th site, 95-th site, 106-th site, 108-th site, 114-th site, 186-th site, 190-th site, 191-th site, 249-th site, 257-th site, 393-th site, 436-th site, 499-th site, 500-th site, 501-th site, 503-th site, 504-th site, 559-th site, and 560-th site, and the mutation is that a methionine in the 45-th site is mutated into a threonine; an alanine in the 95-th site is mutated into a threonine; a cysteine in the 106-th site is mutated into a serine; a threonine in the 108-th site is mutated into a serine; a methionine in the 114-th site is mutated into a leucine, a methionine in the 186-th site is mutated into an isoleucine, a proline in the 190-th site is mutated into a glutamine, a glycine, an arginine, an asparagine, a glutamic acid, a valine, a threonine, an isoleucine, a histidine, a tyrosine, a phenylalanine or a leucine, a leucine in the 191-th site is mutated into a valine, a cysteine in the 249-th site is mutated into a valine, a cysteine in the 257-th site is mutated into an alanine, a cysteine in the 393-th site is mutated into a valine, a cysteine in the 436-th site is mutated into a serine, a leucine in the 499-th site is mutated into an alanine, a glycine in the 500-th site is mutated into a leucine, a serine in the 501-th site is mutated into a threonine, an isoleucine in the 503-th site is mutated into an alanine, a proline in the 504-th site is mutated into a threonine, a valine or a serine, a tyrosine in the 559-th site is mutated into a phenylalanine, a lysine, a methionine, a proline, a glutamine, an asparagine, a serine, an arginine, a valine, an aspartic acid, an isoleucine, a serine, a leucine or an alanine and a tyrosine in the 560-th site is mutated into a phenylalanine, a leucine, a serine, a proline, a methionine, or a alanine; or the amino acid sequence of the monooxygenase mutant is an amino acid sequence having the mutation sites in the mutated amino acid sequence, and having more than 80% of homology with the mutated amino acid sequence.
Preferably, the mutation at least includes one of the following mutation site combinations: a tyrosine in the 559-th site is mutated into a lysine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a proline and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a glutamine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an asparagines and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a threonine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an arginine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a valine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an aspartic acid and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an isoleucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an alanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a serine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 560-th site is mutated into a serine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a glutamine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th is mutated into a glycine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into an arginine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into an asparagine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a phenylalanine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a glutamic acid; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a valine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a threonine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into an isoleucine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a histidine; a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a tyrosine; a tyrosine in the 560-th site is mutated into a proline and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an alanine, a tyrosine in the 560-th site is mutated into a methionine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an alanine, a tyrosine in the 560-th site is mutated into an phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an alanine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a phenylalanine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a phenylalanine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th is mutated into a leucine; a tyrosine in the 559-th site is mutated into a histidine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a lysine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a leucine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a leucine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a glutamine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into an asparagine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a proline, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a glutamine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a serine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a serine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a serine, a tyrosine in the 560-th site is mutated into a proline and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a threonine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a threonine, a tyrosine in the 560-th site is mutated into a glycine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a threonine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a valine, a tyrosine in the 560-th site is mutated into an alanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a valine, a tyrosine in the 560-th site is mutated into a phenylalanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a valine, a tyrosine in the 560-th site is mutated into a leucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a valine, a tyrosine in the 560-th site is mutated into a glutamine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a proline in the 504-th site is mutated into an alanine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a proline in the 504-th site is mutated into an isoleucine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, an asparagines in the 503-th site is mutated into a valine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a proline in the 504-th site is mutated into a threonine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a proline in the 504-th site is mutated into a valine and a proline in the 190-th site is mutated into a leucine; a tyrosine in the 559-th site is mutated into a methionine, a proline in the 504-th site is mutated into a serine and a proline in the 190-th site is mutated into a leucine. Preferably, the mutation at least includes one of the following mutation site combinations: a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a methionine in the 45-th site mutated into a threonine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a cysteine in the 257-th site is mutated into an alanine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a cysteine in the 249-th site is mutated into a valine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a cysteine in the 393-th site is mutated into a valine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine and a methionine in the 186-th site is mutated into an isoleucine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine, a cysteine in the 249-th site is mutated into a valine and a cysteine in the 393-th site is mutated into a valine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine, a cysteine in the 249-th site is mutated into a valine, a cysteine in the 393-th site is mutated into a valine and a cysteine in the 257-th site is mutated into an alanine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine, a cysteine in the 249-th site is mutated into a valine, a cysteine in the 393-th site is mutated into a valine, a cysteine in the 257-th site is mutated into an alanine and a methionine in the 45-th site is mutated into a threonine; a proline in the 190-th site is mutated into a leucine, a tyrosine in the 559-th site is mutated into a methionine, a cysteine in the 249-th site is mutated into a valine, a cysteine in the 393-th site is mutated into a valine, a cysteine in the 257-th site is mutated into an alanine, a methionine in the 45-th site is mutated into a threonine and a methionine in the 186-th site is mutated into an isoleucine. The monooxygenase mutant of the disclosure is based on the monooxygenase shown in the SEQ ID NO: 1, and mutated through a method of site-directed mutagenesis, thereby the amino acid sequence thereof is changed to achieve changes in protein structure and function, and the monooxygenase with the above mutation sites is obtained by a method of directional screening. The monooxygenase mutant of the disclosure has an advantage of greatly improving the enzyme activity, and the selectivity of the enzyme is greatly improved, and the by-product sulfone content is greatly reduced, thereby a cost in industrial production of the chiral sulfoxide is greatly reduced.
According to a typical implementation mode of the disclosure, a DNA molecule is provided. The DNA molecule encodes the above monooxygenase mutant. The monooxygenase obtained by the above DNA encoding improves the enzyme activity and the enzyme selectivity, reduces the content of the by-product sulfone, reduces the amount of the added enzyme in industrial production of a chiral sulfoxide, and reduces the difficulty of post-treatment separation and purification.
The above DNA molecule of the disclosure may also exist in the form of an “expression cassette”. The “expression cassette” refers to a linear or circular nucleic acid molecule, including DNA and RNA sequences that may direct the expression of a specific nucleotide sequence in an appropriate host cell. Generally speaking, it includes a promoter operatively linked with a target nucleotide, and optionally it is operatively linked with a termination signal and/or other regulatory elements. The expression cassette may also include sequences required for proper translation of the nucleotide sequence. An encoding region usually encodes the target protein, but also encodes a target functional RNA in a sense or antisense direction, such as an antisense RNA or an untranslated RNA. The expression cassette containing a target polynucleotide sequence may be chimeric, it means that at least one of components thereof is heterologous to at least one of the other components thereof. The expression cassette may also naturally exist, but is obtained by efficient recombination for heterologous expression.
According to a typical implementation mode of the disclosure, a recombinant plasmid is provided. The recombinant plasmid contains any one of the above DNA molecules. The DNA molecule in the above recombinant plasmid is placed in a suitable position of the recombinant plasmid, so that the above DNA molecule may be replicated, transcripted or expressed correctly and smoothly.
Although a qualifier used in the disclosure to define the above DNA molecule is “containing”, it does not mean that other sequences which are not related to a function thereof may be arbitrarily added to both ends of the DNA sequence. It is known by those skilled in the art that in order to meet requirements of a recombination operation, it is necessary to add appropriate restriction endonuclease digestion sites at both ends of the DNA sequence, or add additional a start codon, a stop codon and the like. Therefore, if a closed expression is used to limit, these situations may not be truly covered.
A term “plasmid” used in the disclosure includes any plasmids, cosmids, bacteriophages or agrobacterium binary nucleic acid molecules in double-stranded or single-stranded linear or circular form, preferably a recombinant expression plasmid, it may be a prokaryotic expression plasmid, and may also be a eukaryotic expression plasmid, but preferably the prokaryotic expression plasmid. In some implementation schemes, the recombinant plasmid is selected from pET-22b(+), pET-22b(+), pET-3a(+), pET-3d(+)), pET-11a(+), pET-12a(+), pET-14b(+), pET-15b(+), pET-16b(+), pET-17b(+), pET-19b(+), PET-20b(+), pET-21a(+), pET-23a(+), pET-23b(+), pET-24a(+), pET-25b(+), pET-26b(+), pET-27b(+), pET-28a(+), pET-29a(+), pET-30a(+), pET-31b(+), pET-32a(+), pET-35b(+), pET-38b(+), pET-39b(+), pET-40b(+), pET-41a(+), pET-41b(+), pET-42a(+), pET-43a(+), pET-43b(+), pET-44a(+), pET-49b(+), pQE2, pQE9, pQE30, pQE31, pQE32, pQE40, pQE70, pQE80, pRSET-A, pRSET-B, pRSET-C, pGEX-5X-1, pGEX-6p-1, pGEX-6p-2, pBV220, pBV221, pBV222, pTrc99A, pTwin1, pEZZ18, pKK232-18, pUC-18 or pUC-19. More preferably, the above recombinant plasmid is pET-22b(+).
According to a typical implementation mode of the disclosure, a host cell is provided. The host cell contains any one of the above recombinant plasmids. The host cell suitable for the disclosure includes but is not limited to a prokaryotic cell, a yeast or a eukaryotic cell. Preferably, the prokaryotic cell is eubacteria, for example, gram-negative bacteria or gram-positive bacteria. More preferably, the prokaryotic cell is an E. coli BL21 cell or an E. coli DH5α competent cell. The best conditions for inducing the expression of the monooxygenase: 25° C., inducing with 0.1 mM IPTG for 16 h. The mutant plasmid is transformed into the E. coli cells, and then a crude enzyme is obtained by a method of ultrasonically breaking the cells.
According to a typical implementation mode of the disclosure, a method for producing a chiral sulfoxide is provided. The method includes a step of performing a catalytic monooxygenation reaction on a thioether compound by a monooxygenase, herein the monooxygenase is any one of the above monooxygenase mutants. Because the above monooxygenase mutant of the disclosure has higher enzyme catalytic activity and higher selectivity, the chiral sulfoxide prepared by using the monooxygenase mutant of the disclosure may not only reduce the production cost, but also an ee value of the obtained chiral sulfoxide is greater than 99%, and a de value is greater than 99%.
In a typical implementation mode of the disclosure the thioether compound is
Figure US12098394-20240924-C00003
herein R1 and R2 are each independently a C1˜C8 alkyl, a C5˜C10 cycloalkyl, a C5˜C10 aryl or a C5˜C10 heteroaryl, or the R1 and R2 together with a carbon on a carbonyl group form a C5˜C10 heterocyclic group, a C5˜C10 carbocyclic group or a C5˜C10 heteroaryl, heteroatoms in the C5˜C10 heterocyclic group and C5˜C10 heteroaryl are each independently selected from at least one of nitrogen, oxygen and sulfur, and an aryl in the C5˜C10 aryl, a heteroaryl in the C5˜C10 heteroaryl, a carbocyclic group in the C5˜C10 carbocyclic group or a heterocyclic group in the C5˜C10 heterocyclic group is each independently unsubstituted or substituted with at least one group of a halogen, an alkoxy or an alkyl.
Typically,
Figure US12098394-20240924-C00004
the thioether compound is
Figure US12098394-20240924-C00005
(1-(3-chlorophenyl)cyclopropyl)methyl sulfide).
The monooxygenase may be cell lysate enzyme solution, a whole cell, freeze-dried enzyme powder, a freeze-dried cell, an immobilized enzyme or an immobilized cell of the monooxygenase mutant.
Beneficial effects of the disclosure are further described below in combination with the embodiments.
Embodiment 1
16 mg of (1-(3-chlorophenyl)cyclopropyl)methyl sulfide is added to 10 mL of a reaction flask, 0.1 M of Tris-HCl 9.0, 20 mg of isopropanol, 0.16 mg of NADP+, 1.6 mg of alcohol dehydrogenase freeze-dried enzyme powder, and 1.6 mg of monooxygenase BVMO freeze-dried enzyme powder are added, and mixed uniformly. A total volume is 1 mL. It is reacted at 30° C. on a 200-revolution shaker for 16 hours. 3 mL of acetonitrile is added to a reaction sample system, it is placed in 5 mL of an EP tube after mixing uniformly, and centrifuged at 12,000 rpm for 3 minutes. 100 μL of supernatant is taken and put in a sample delivery bottle, 900 μL of 90% acetonitrile is added, and it is detected by HPLC with a detection wavelength of 210 nm. Results are shown in Table 1.
TABLE 1
Mutant Activity Sulfone content
WT − *
M45T + *
V95I + **
C106S + *
T108S + *
M114L + *
M186I + *
P190F + **
P190L ++ **
L191V + **
C249V + *
C257A + *
C393V + *
C436S + *
L499A + **
G500L ++ **
S501T + **
I503A + **
Y559F +++ **
Y559L ++ ***
Y559A +++ ***
Y560F +++ ***
Y560L ++ ***
Y560A ++ **
Compared with the SEQ ID NO: 1, the enzyme activity is improved by multiple times, + represents 1-2 times of improvement, ++ represents 3-5 times of improvement, and +++ represents 5-10 times of improvement.
20-30% of the sulfone content is represented by *, 2-20% of the content is represented by **, and less than 2% of the content is represented by ***.
Enzyme solution preparation method: a supernatant medium is removed by centrifugation in a 96-well plate, 200 μL of enzymatic hydrolysis solution (lysozyme 2 mg/mL, polymyxin 0.5 mg/mL, pH=7.0) is added to each well, a temperature is kept at 37° C. for 3 h.
High-throughput screening method: 250 μL bioassay system: 2 mM of a substrate final concentration, 0.3 mM of a NADPH final concentration, 100 μL of an addition amount of cell lysate enzyme solution, pH=9.0, and 30° C. of a temperature.
The mutant obtained by screening is cultured in a shake flask, and then subjected to an amplification reaction.
The best conditions for inducing the expression of the monooxygenase: 25° C., inducing with 0.1 mM IPTG overnight.
Embodiment 2
20 mg of (1-(3-chlorophenyl)cyclopropyl)methyl sulfide is added to 10 mL of a reaction flask, 0.1 M of Tris-HCl 9.0, 20 mg of isopropanol, 0.2 mg of NADP+, 20 mg of an alcohol dehydrogenase, and 20 mg of a monooxygenase BVMO are added, and mixed uniformly. A total volume is 1 mL. It is reacted at 30° C. on a 200-revolution shaker for 16 hours. 3 mL of acetonitrile is added to a reaction sample system, it is placed in 5 mL of an EP tube after mixing uniformly, and centrifuged at 12,000 rpm for 3 minutes. 100 μL of supernatant is taken and put in a sample delivery bottle, 900 μL of 90% acetonitrile is added, and it is detected by HPLC with a detection wavelength of 210 nm.
A transformation effect of a single-site mutant is higher than that of a female parent, but it does not achieve the desired effect. A combined saturation mutation may obtain a mutant with a synergistic effect between several mutation sites, and compositions of an amino acid thereof may be optimized and combined. Results are shown in Table 2.
TABLE 2
Mutant Activity Sulfone content
WT − *
P190Q + Y560F ++ **
P190G + Y560F +++ **
P190R + Y560F + *
P190N + Y560F +++ *
P190F + Y560F + ***
P190E + Y560F +++ *
P190V + Y560F +++ ***
P190T + Y560F +++ **
P190L + Y560F ++++ **
P190I + Y560F ++++ ***
P190H + Y560F ++++ ***
P190Y + Y560F ++++ **
Y559K + P190L ++++ ***
Y559M + P190L +++++ ***
Y559P + P190L ++++ **
Y559Q + P190L ++++ ***
Y559L + P190L ++++ **
Y559N + P190L ++++ **
Y559T + P190L ++++ **
Y559R + P190L ++++ **
Y559V + P190L ++++ **
Y559D + P190L +++ **
Y559I + P190L ++++ **
Y559A + P190L ++++ ***
Y559S + P190L ++++ **
Y560L + P190L +++++ ***
Y560S + P190L +++ **
Y560P + P190L +++ **
Y559A + Y560M + P190L ++++ **
Y559A + Y560F + P190L ++++ ***
Y559A + Y560L + P190L ++++ ***
Y559F + Y560F + P190L +++ **
Y559F + Y560L + P190L +++ **
Y559H + Y560L + P190L ++++ ***
Y559K + Y560L + P190L ++++ ***
Y559L + Y560F + P190L +++ **
Y559L + Y560L + P190L +++ ***
Y559Q + Y560F + P190L ++++ ***
Y559M + Y560F + P190L +++++ **
Y559N + Y560L + P190L ++++ ***
Y559P + Y560L + P190L +++ **
Y559Q + Y560L + P190L ++++ ***
Y559S + Y560F + P190L +++ **
Y559S + Y560L + P190L ++++ ***
Y559S + Y560P + P190L + **
Y559T + Y560F + P190L +++ **
Y559T + Y560G + P190L + **
Y559T + Y560L + P190L +++ **
Y559V + Y560A + P190L ++ *
Y559V + Y560F + P190L +++ *
Y559V + Y560L + P190L ++++ ***
Y559V + Y560Q + P190L ++ **
Y559M + P190L + P504A +++ ***
Y559M + P190L + P504I ++ ***
Y559M + P190L + N503V +++ ***
Y559M + P190L + P504T +++++ ***
Y559M + P190L + P504V ++++ **
Y559M + P190L + P504S ++++ **
Compared with the SEQ ID NO: 1, the enzyme activity is improved by multiple times, + represents 1-2 times of improvement, ++ represents 3-5 times of improvement, +++ represents 5-10 times of improvement, ++++ represents 10-20 times of improvement, and +++++ represents 20 times of improvement.
20-30% of the sulfone content is represented by *, 2-20% of the content is represented by **, and less than 2% of the content is represented by ***.
Combination of mutation sites may obtain the better mutant. Therefore, the mutation sites are randomly recombined by a method of DNA shuffling, to build a mutation library, and then it is screened to try to get the better mutant.
DNA shuffling is sexual recombination of genes at a molecular level. A group of homologous genes are digested with a nuclease I into random fragments, a library is formed by these random fragments, and PCR amplification is performed by using these random fragments as primers and templates mutually. While one gene copy fragment is used as a primer for another gene copy, template exchange and gene recombination occur.
Enzyme solution preparation method: a supernatant medium is removed by centrifugation in a 96-well plate, 200 μL of enzymatic hydrolysis solution (lysozyme 2 mg/mL, polymyxin 0.5 mg/mL, pH=7.0) is added to each well, a temperature is kept at 37° C. for 3 h.
High-throughput screening method: 250 μL bioassay system: 2 mM of a substrate final concentration, 0.3 mM of a NADPH final concentration, 100 μL of an addition amount of cell lysate enzyme solution, pH=9.0, and 30° C. of a temperature.
The mutant obtained by screening is cultured in a shake flask, and then subjected to an amplification reaction.
The best conditions for inducing the expression of the monooxygenase: 25° C., inducing with 0.1 mM IPTG overnight.
Embodiment 3
30 mg of (1-(3-chlorophenyl)cyclopropyl)methyl sulfide is added to 10 mL of a reaction flask, 0.1 M of Tris-HCl 9.0, 30 mg of isopropanol, 0.3 mg of NADP+, 30 mg of an alcohol dehydrogenase, and 30 mg of a monooxygenase BVMO are added, and mixed uniformly. A total volume is 1 mL. It is reacted at 30° C. on a 200-revolution shaker for 16 hours. 3 mL of acetonitrile is added to a reaction sample system, it is placed in 5 mL of an EP tube after mixing uniformly, and centrifuged at 12,000 rpm for 3 minutes. 100 μL of supernatant is taken and put in a sample delivery bottle, 900 μL of 90% acetonitrile is added, and it is detected by HPLC with a detection wavelength of 210 nm. Results are shown in Table 3.
TABLE 3
Mutant Activity Sulfone content
WT − *
P190L + Y559M + M45T +++++ ***
P190L + Y559M + C257A +++++ ***
P190L + Y559M + C249V +++++ ***
P190L + Y559M + C393V +++++ ***
P190L + Y559M + M186I +++++ ***
P190L + Y559M + C249V + C393V +++++ ***
P190L + Y559M + C249V + C393V + C257A +++++ ***
P190L + Y559M + C249V + C393V + +++++ ***
C257A + M45T
P190L + Y559M + C249V + C393V + +++++ ***
C257A + M45T + M186I
Compared with the SEQ ID NO: 1, the enzyme activity is improved by multiple times, + represents 1-2 times of improvement, ++ represents 3-5 times of improvement, +++ represents 5-10 times of improvement, ++++ represents 10-20 times of improvement, and +++++ represents 20 times of improvement.
20-30% of the sulfone content is represented by *, 2-20% of the content is represented by **, and less than 2% of the content is represented by ***.
The above are only preferred embodiments of the disclosure, and are not intended to limit the disclosure. Various modifications and changes may be made to the disclosure by those skilled in the art. Any modifications, equivalent replacements, improvements and the like made within the spirit and principle of the disclosure should be included in a scope of protection of the disclosure.

Claims (9)

The invention claimed is:
1. A monooxygenase mutant having monooxygenase activity, wherein the monooxygenase mutant comprises all of SEQ ID NO: 1 except for one of the substitutions selected from the group consisting of:
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with lysine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with proline and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with glutamine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with asparagine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with threonine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with arginine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with valine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with aspartic acid and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with isoleucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with alanine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with serine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with alanine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with methionine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with alanine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with phenylalanine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with alanine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with phenylalanine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with phenylalanine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with phenylalanine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with histidine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with lysine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with leucine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with phenylalanine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with leucine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with glutamine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with phenylalanine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with phenylalanine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with asparagine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with proline, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with glutamine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with serine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with phenylalanine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with serine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with serine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with proline and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with threonine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with phenylalanine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with threonine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with glycine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with threonine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with valine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with alanine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with valine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with phenylalanine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with valine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with leucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with valine, the amino acid at the position corresponding to position 560 of the polypeptide of SEQ ID NO: 1 is replaced with glutamine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine, the amino acid at the position corresponding to position 504 of the polypeptide of SEQ ID NO: 1 is replaced with alanine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine, the amino acid at the position corresponding to position 504 of the polypeptide of SEQ ID NO: 1 is replaced with isoleucine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine, the amino acid at the position corresponding to position 503 of the polypeptide of SEQ ID NO: 1 is replaced with valine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine, the amino acid at the position corresponding to position 504 of the polypeptide of SEQ ID NO: 1 is replaced with threonine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine, the amino acid at the position corresponding to position 504 of the polypeptide of SEQ ID NO: 1 is replaced with valine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine, the amino acid at the position corresponding to position 504 of the polypeptide of SEQ ID NO: 1 is replaced with serine and the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine;
the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine, the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine and the amino acid at the position corresponding to position 45 of the polypeptide of SEQ ID NO: 1 is replaced with threonine;
the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine, the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine and the amino acid at the position corresponding to position 257 of the polypeptide of SEQ ID NO: 1 is replaced with alanine;
the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine, the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine and the amino acid at the position corresponding to position 249 of the polypeptide of SEQ ID NO: 1 is replaced with valine;
the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine, the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine and the amino acid at the position corresponding to position 393 of the polypeptide of SEQ ID NO: 1 is replaced with valine;
the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine, the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine and the amino acid at the position corresponding to position 186 of the polypeptide of SEQ ID NO: 1 is replaced with isoleucine;
the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine, the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine, the amino acid at the position corresponding to position 249 of the polypeptide of SEQ ID NO: 1 is replaced with valine and the amino acid at the position corresponding to position 393 of the polypeptide of SEQ ID NO: 1 is replaced with valine;
the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine, the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine, the amino acid at the position corresponding to position 249 of the polypeptide of SEQ ID NO: 1 is replaced with valine, the amino acid at the position corresponding to position 393 of the polypeptide of SEQ ID NO: 1 is replaced with valine and the amino acid at the position corresponding to position 257 of the polypeptide of SEQ ID NO: 1 is replaced with alanine;
the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine, the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine, the amino acid at the position corresponding to position 249 of the polypeptide of SEQ ID NO: 1 is replaced with valine, the amino acid at the position corresponding to position 393 of the polypeptide of SEQ ID NO: 1 is replaced with valine, the amino acid at the position corresponding to position 257 of the polypeptide of SEQ ID NO: 1 is replaced with alanine and the amino acid at the position corresponding to position 45 of the polypeptide of SEQ ID NO: 1 is replaced with threonine; and
the amino acid at the position corresponding to position 190 of the polypeptide of SEQ ID NO: 1 is replaced with leucine, the amino acid at the position corresponding to position 559 of the polypeptide of SEQ ID NO: 1 is replaced with methionine, the amino acid at the position corresponding to position 249 of the polypeptide of SEQ ID NO: 1 is replaced with valine, the amino acid at the position corresponding to position 393 of the polypeptide of SEQ ID NO: 1 is replaced with valine, the amino acid at the position corresponding to position 257 of the polypeptide of SEQ ID NO: 1 is replaced with alanine, the amino acid at the position corresponding to position 45 of the polypeptide of SEQ ID NO: 1 is replaced with threonine and the amino acid at the position corresponding to position 186 of the polypeptide of SEQ ID NO: 1 is replaced with isoleucine.
2. A method for producing a chiral sulfoxide, comprising a step of performing a catalytic monooxygenation reaction on a thioether compound by a monooxygenase, wherein the monooxygenase is the monooxygenase mutant according to claim 1, and the thioether compound is
Figure US12098394-20240924-C00006
((1-(3-chlorophenyl)cyclopropyl)methyl sulfide).
3. The method according to claim 2, wherein the monooxygenase is in the form of an enzyme solution, a whole cell, freeze-dried enzyme powder, a freeze-dried cell, an immobilized enzyme or an immobilized cell.
4. The method according to claim 2, wherein the catalytic monooxygenation reaction requires a cofactor circulation system, wherein the cofactor circulation system is a NAD/NADH or a NADP/NADPH cofactor circulation system, and wherein the cofactor circulation system comprises (i) glucose and glucose dehydrogenase, (ii) formate and formate dehydrogenase, (iii) glucose-6-phosphate and glucose-6-phosphate dehydrogenase, or (iv) a secondary alcohol and a secondary alcohol dehydrogenase.
5. The method according to claim 2, wherein the amount of the monooxygenase in the catalytic monooxygenation reaction is 0.1 to 10 times the amount of the thioether.
6. The method according to claim 2, wherein the temperature of the monooxygenation reaction is 10-50° C.
7. The method according to claim 2, wherein the monooxygenation reaction is performed at a pH of 7-10.
8. The method according to claim 2, wherein the temperature of the monooxygenation reaction is 30° C.
9. The method according to claim 2, wherein the monooxygenation reaction is performed at a pH of 9.
US17/290,749 2018-11-05 2018-11-05 Monooxygenase mutant and use thereof Active 2039-01-28 US12098394B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2018/113938 WO2020093191A1 (en) 2018-11-05 2018-11-05 Monooxygenase mutant and application thereof

Publications (2)

Publication Number Publication Date
US20220002683A1 US20220002683A1 (en) 2022-01-06
US12098394B2 true US12098394B2 (en) 2024-09-24

Family

ID=70611243

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/290,749 Active 2039-01-28 US12098394B2 (en) 2018-11-05 2018-11-05 Monooxygenase mutant and use thereof

Country Status (4)

Country Link
US (1) US12098394B2 (en)
EP (1) EP3878953A4 (en)
JP (1) JP7293351B2 (en)
WO (1) WO2020093191A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115232799B (en) * 2022-01-05 2024-08-09 中国科学院成都生物研究所 Styrene monooxygenase mutant and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042436A2 (en) 1999-12-10 2001-06-14 E.I. Du Pont De Nemours And Company Genes involved in cyclododecanone degradation pathway
CN105695425A (en) 2014-11-26 2016-06-22 南京博优康远生物医药科技有限公司 Cyclohexanone monooxygenase and application thereof in synthesis of esomeprazole
CN106754802A (en) 2017-01-17 2017-05-31 深圳大学 Isoeugenol monooxygenase mutant and its application
CN108300707A (en) 2018-02-07 2018-07-20 凯莱英医药集团（天津）股份有限公司 A kind of monooxygenase mutant and its preparation method and application

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105296B2 (en) 2001-08-29 2006-09-12 E. I. Du Pont De Nemours And Company Genes encoding Baeyer-Villiger monooxygenases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042436A2 (en) 1999-12-10 2001-06-14 E.I. Du Pont De Nemours And Company Genes involved in cyclododecanone degradation pathway
CN105695425A (en) 2014-11-26 2016-06-22 南京博优康远生物医药科技有限公司 Cyclohexanone monooxygenase and application thereof in synthesis of esomeprazole
CN106754802A (en) 2017-01-17 2017-05-31 深圳大学 Isoeugenol monooxygenase mutant and its application
CN108300707A (en) 2018-02-07 2018-07-20 凯莱英医药集团（天津）股份有限公司 A kind of monooxygenase mutant and its preparation method and application

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"R. ruber cyclododecanone monooxygenase enzyme"; Database acession No. AAB85324; Jun. 15, 2007; sequence.
Database Uniprot; "monooxygenase from Atreptosporangium sp.‘caverna’ "; Database Accession No. AoA2Z3UFR4; Oct. 10, 2018; sequence.
GenBank Accession No. AAL14233; GenBank Database, Oct. 17, 2001.
GenBank accession No. WP_110694042, Jul. 8, 2018. *
Gomez-Escribano, GenBank accession No. CQR60781, May 21, 2015. *
Kostichka, Kristy et al; "Cloning and Characterization of a Gene Cluster for Cyclododecanone Oxidation in Rhodococcus ruber SC1"; Journal of Bacteriology; vol. 183, No. 21; Nov. 2001; pp. 6478-6486.
Liang, Qiuling et al.; Nonconserved Hinge in Baeyer-Villiger Monooxygenase Affects Catalytic Activity and Stereoselectivity; Chinese Journal of Biotechnology, vol. 31, No. 3, Mar. 25, 2015, ISSN: 1000-361, pp. 361-374.
Sadowski et al., Current Opinion in Structural Biology 19:357-362, 2009. *
Seffernick et al., J. Bacteriol. 183(8):2405-2410, 2001. *
Singh et al., Current Protein and Peptide Science 19(1):5-15, 2018. *
Tang et al., Phil Trans R Soc B 368:20120318, 1-10, 2013. *
Witkowski et al., Biochemistry 38:11643-11650, 1999. *

Also Published As

Publication number Publication date
JP2022512839A (en) 2022-02-07
EP3878953A1 (en) 2021-09-15
JP7293351B2 (en) 2023-06-19
EP3878953A4 (en) 2022-08-10
WO2020093191A1 (en) 2020-05-14
US20220002683A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
CN109402074B (en) Monooxygenase mutants and uses thereof
CN108048417B (en) Ketoreductase mutant and application thereof
US11702640B2 (en) Monooxygenase mutant, preparation method and application thereof
CN110257351B (en) Ketoreductase mutant and method for producing chiral alcohol
JP6988000B2 (en) Ketoreductase variants and their applications
US11407982B2 (en) Transaminase mutant and use thereof
US20240084271A1 (en) Amino Acid Dehydrogenase Mutant and use thereof
EP4276178A1 (en) Esterase mutant and use thereof
US20230227797A1 (en) Transaminase mutant and use thereof
US12098394B2 (en) Monooxygenase mutant and use thereof
US11603521B2 (en) Amino acid dehydrogenase mutant and use thereof
CN110713992B (en) Ketoreductase mutant and method for producing chiral alcohol
JP7263557B2 (en) Aminotransferase mutants and their applications
JP7498244B2 (en) Monooxygenase mutants and uses thereof
JP7375052B2 (en) Ketoreductase mutant and method for producing chiral alcohol
CN110055230B (en) Monooxygenase mutants and uses thereof
JP7534403B2 (en) Ketoreductase mutants and methods for producing chiral alcohols
CN114807066A (en) Ketoreductase mutant
EP4414448A1 (en) Transaminase mutant and use thereof
CN114807246A (en) Method for producing chiral alcohol

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD., CHINA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HONG, HAO;JAMES, GAGE;LU, JIANGPING;AND OTHERS;REEL/FRAME:056107/0741

Effective date: 20210302

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE